Nicholas Farinola

474 total citations
15 papers, 351 citations indexed

About

Nicholas Farinola is a scholar working on Infectious Diseases, Economics and Econometrics and Oncology. According to data from OpenAlex, Nicholas Farinola has authored 15 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 4 papers in Economics and Econometrics and 3 papers in Oncology. Recurrent topics in Nicholas Farinola's work include Health Systems, Economic Evaluations, Quality of Life (4 papers), Tuberculosis Research and Epidemiology (3 papers) and Mosquito-borne diseases and control (2 papers). Nicholas Farinola is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (4 papers), Tuberculosis Research and Epidemiology (3 papers) and Mosquito-borne diseases and control (2 papers). Nicholas Farinola collaborates with scholars based in Australia, United States and India. Nicholas Farinola's co-authors include Neil Piller, Yada Kanjanapan, Amy S. Espeseth, Tal Zaks, Antonios O. Aliprantis, Lori Panther, Igor Smolenov, Eseng Lai, Daniel S. Spellman and Paul Griffin and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, The Lancet Infectious Diseases and Vaccine.

In The Last Decade

Nicholas Farinola

14 papers receiving 330 citations

Peers

Countries citing papers authored by Nicholas Farinola

Since Specialization

Citations

This map shows the geographic impact of Nicholas Farinola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Farinola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Farinola more than expected).

Fields of papers citing papers by Nicholas Farinola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Farinola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Farinola. The network helps show where Nicholas Farinola may publish in the future.

Co-authorship network of co-authors of Nicholas Farinola

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Farinola. A scholar is included among the top collaborators of Nicholas Farinola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Farinola. Nicholas Farinola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia 2024 ·The Lancet Infectious Diseases ·Bhagwat Gunale, Nicholas Farinola, Chandrashekhar D. Kamat, (unknown), Sambhaji S. Pisal, Rajeev Dhere, Claire A. Miller, Prasad S. Kulkarni	8
2	A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults 2023 ·Vaccine ·Bhagwat Gunale, Nicholas Farinola, (unknown), Shubham Shrivastava, (unknown), (unknown), Rajeev Dhere, Vidya A. Arankalle, Akhilesh Chandra Mishra, (unknown), Prasad S. Kulkarni	2
3	HAE PROPHYLAXIS BY TARGETING PREKALLIKREIN WITH SIRNA- PHASE 1 INTERIM SAFETY OUTCOMES AND PREKALLIKREIN LEVELS 2023 ·Annals of Allergy Asthma & Immunology ·William T. Smith, Nicholas Farinola, (unknown), (unknown), Robert J. Wong, Ruixia Zhu, Zhimin Li	1
4	A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults 2020 ·Human Vaccines & Immunotherapeutics ·Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha Railkar, (unknown), Wen Liu, Jeffrey R. Sachs, (unknown), Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther	111
5	Frailty and Co-Prescribing of Potentially Interacting Drugs in New Users of Warfarin 2020 ·Drugs & Aging ·(unknown), (unknown), Maarit Jaana Korhonen, J. Simon Bell, Nicholas Farinola, (unknown), Sepehr Shakib, Risto Huupponen	2
6	Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma 2019 ·Ingmar Bruns, (unknown), George Mensing, (unknown), Katerina Pardali, (unknown), (unknown), (unknown), Marita Olsson, Cyrus Ghobadi, (unknown), (unknown), Nicholas Farinola, (unknown), (unknown)	4
7	Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects 2019 ·Antimicrobial Agents and Chemotherapy ·Paul B. Eckburg, Troy Lister, Susannah M. Walpole, (unknown), Luke Utley, John Tomayko, (unknown), Nicholas Farinola, (unknown)	41
8	The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial 2019 ·Inflammatory Bowel Diseases ·Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, Jean‐Frédéric Colombel, (unknown), Marion Ehrich, Nicholas Farinola, Josep Bassaganya‐Riera	16
9	Development and validation of the Medication Regimen Simplification Guide for Residential Aged CarE (MRS GRACE) 2018 ·Clinical Interventions in Aging ·Esa Y. H. Chen, Janet K. Sluggett, Jenni Ilomäki, Sarah N. Hilmer, Megan Corlis, (unknown), Laura Dean, Christopher P Alderman, Nicholas Farinola, (unknown), (unknown), (unknown), (unknown), Solomon Yu, J. Simon Bell	29
10	Pharmacokinetics, Safety, and Tolerability Evaluation of Single and Multiple Doses of GSK3342830 in Healthy Volunteers 2018 ·Clinical Pharmacology in Drug Development ·David M. Tenero, Nicholas Farinola, Elchonon M. Berkowitz, Courtney Tiffany, (unknown), Zhengyu Xue, Aparna Raychaudhuri, David Gardiner	16
11	Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing? 2017 ·Therapeutic Advances in Drug Safety ·Nicholas Farinola, Gillian E. Caughey, J. Simon Bell, (unknown), (unknown), Sepehr Shakib	7
12	Comprehensive guide to biological agents 2017 ·The Medical Journal of Australia ·Nicholas Farinola	0
13	Denosumab‐induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure 2013 ·Internal Medicine Journal ·Nicholas Farinola, Yada Kanjanapan	30
14	CYP2A6Polymorphisms: Is there a Role for Pharmacogenomics In Preventing Coumarin-Induced Hepatotoxicity in Lymphedema Patients? 2007 ·Pharmacogenomics ·Nicholas Farinola, Neil Piller	19
15	Pharmacogenomics: Its Role in Re-establishing Coumarin as Treatment for Lymphedema 2005 ·Lymphatic Research and Biology ·Nicholas Farinola, Neil Piller	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact